One-Year Outcomes of Laparoscopic Adjustable Gastric Banding Based on Bariatric Analysis and Reporting Outcome System (BAROS) in Morbidly Obese Korean Patients.
- Author:
Jong Seob PARK
1
;
Sang Moon HAN
Author Information
1. Department of Surgery, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea. surgeryhan@gmail.com
- Publication Type:Original Article
- Keywords:
Bariatric surgery;
Adjustable Gastric banding;
BAROS
- MeSH:
Bariatric Surgery;
Body Mass Index;
C-Peptide;
Female;
Humans;
Insulin;
Insulin Resistance;
Male;
Prospective Studies;
Quality of Life;
Retrospective Studies;
Triglycerides;
Uric Acid;
Weight Loss
- From:Journal of Metabolic and Bariatric Surgery
2016;5(2):67-72
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study aimed to compare amount of weight loss, serum laboratory results, and bariatric analysis and reporting outcome system (BAROS) scores obtained before surgery with those obtained 1 year after laparoscopic adjustable gastric banding (AGB). MATERIALS AND METHODS: From January 2013 to November 2014, 32 consecutive patients who underwent AGB were enrolled in this study. This study was a retrospective analysis of our prospectively collected database. The BAROS score included BAROS weight, medical condition, quality of life, and complications recorded 1 year after AGB. Demographic and post-operative data were also collected and analyzed. RESULTS: Thirty-two patients were enrolled in this study, comprising 26 women and 6 men, with an average body mass index of 39.0±6.1 kg/m². The total BAROS score 1 year post AGB was 4.6±1.7, and it was classified as excellent grade. Among them, the quality of life score was 1.8±0.6. Four minor complications were noted. The serum laboratory values improved 1 year post surgery, including hemoglobin A1c, c-peptide, insulin, Homeostatic model assessment of estimated insulin resistance (HOMA IR), Homeostatic model assessment of beta-cell function (HOMA B), triglyceride, total protein, and uric acid. CONCLUSION: AGB showed that it is acceptable in aspect of BAROS outcome as well as weight loss, and serum laboratory result in short-term period.
